Contineum Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
CTNM$10.56+2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(in thousands, except share data)
| Class A and Class BCommon Stock · AdditionalPaid-inCapital · Accumulated OtherComprehensiveIncome (Loss) · AccumulatedDeficit · Total Stockholders'Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||
| Balance at December 31, 2025 | 37,320,125 | $37 | $438,072 | $260 | $(177,380) | $260,989 | |||||
| Exercise of stock options | 66,252 | — | 198 | — | — | 198 | |||||
| Stock-based compensation | — | — | 3,823 | — | — | 3,823 | |||||
| Net loss | — | — | — | — | (14,456) | (14,456) | |||||
| Unrealized loss on marketable securities | — | — | — | (513) | — | (513) | |||||
| Balance at March 31, 2026 | 37,386,377 | $37 | $442,093 | $(253) | $(191,836) | $250,041 | |||||
| Exercise of stock options | 106,275 | — | 473 | — | — | 473 | |||||
| Shares purchased through employee stock purchase plan | 120,757 | 1 | 779 | — | — | 780 | |||||
| Stock-based compensation | — | — | 3,840 | — | — | 3,840 | |||||
| Net loss | — | — | — | — | (15,154) | (15,154) | |||||
| Unrealized loss on marketable securities | — | — | — | (320) | — | (320) | |||||
| Balance at June 30, 2026 | 37,613,409 | $38 | $447,185 | $(573) | $(206,990) | $239,660 | |||||
| Exercise of stock options | 226,695 | — | 1,104 | — | — | 1,104 | |||||
| Issuance of common stock in at-the-market offering | 1,409,443 | 1 | 19,426 | — | — | 19,427 | |||||
| Stock-based compensation | — | — | 4,858 | — | — | 4,858 | |||||
| Net loss | — | — | — | — | (18,697) | (18,697) | |||||
| Unrealized loss on marketable securities | — | — | — | (934) | — | (934) | |||||
| Balance at September 30, 2026 | 39,249,547 | $39 | $472,573 | $(1,507) | $(225,687) | $245,418 | |||||
| Class A and Class BCommon Stock · AdditionalPaid-inCapital · Accumulated Other ComprehensiveIncome · AccumulatedDeficit · TotalStockholders'Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||
| Balance at December 31, 2024 | 25,854,549 | $26 | $315,371 | $71 | $(117,402) | $198,066 | |||||
| Exercise of stock options | 17,000 | — | 24 | — | — | 24 | |||||
| Stock-based compensation | — | — | 2,569 | — | — | 2,569 | |||||
| Net loss | — | — | — | — | (15,990) | (15,990) | |||||
| Unrealized gain on marketable securities | — | — | — | 99 | — | 99 | |||||
| Balance at March 31, 2025 | 25,871,549 | $26 | $317,964 | $170 | $(133,392) | $184,768 | |||||
| Shares purchased through employee stock purchase plan | 48,346 | — | 267 | — | — | 267 | |||||
| Stock-based compensation | — | — | 2,418 | — | — | 2,418 | |||||
| Net loss | — | — | — | — | (16,040) | (16,040) | |||||
| Unrealized loss on marketable securities | — | — | — | (23) | — | (23) | |||||
| Balance at June 30, 2025 | 25,919,895 | $26 | $320,649 | $147 | $(149,432) | $171,390 | |||||
| Issuance of common stock in at-the-market offering, net of issuance costs | 3,241,110 | 3 | 19,009 | — | — | 19,012 | |||||
| Exercise of stock options | 21,506 | — | 173 | — | — | 173 | |||||
| Stock-based compensation | — | — | 2,569 | — | — | 2,569 | |||||
| Net loss | — | — | — | — | (12,792) | (12,792) | |||||
| Unrealized loss on marketable securities | — | — | — | 118 | — | 118 | |||||
| Balance at September 30, 2025 | 29,182,511 | $29 | $342,400 | $265 | $(162,224) | $180,470 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.